Zevra Therapeutics Appoints Justin Renz as New CFO

Zevra Therapeutics ( (ZVRA) ) has shared an announcement.

On March 4, 2026, Zevra appointed industry veteran Justin Renz as Chief Financial Officer and Treasurer, effective March 9, 2026, and principal financial officer, effective March 10, 2026, with an employment package that includes a $520,000 base salary, performance-based bonus eligibility and stock options vesting over four years. Renz, whose background includes senior finance roles at Ardelyx, Correvio Pharma, Karyopharm Therapeutics and Zalicus, replaces interim principal financial officer Timothy Sangiovanni and is expected to add seasoned transactional and commercial-stage expertise as Zevra scales its rare-disease portfolio.

For the fourth quarter of 2025, Zevra reported net revenue of $34.1 million, up 31% sequentially, driven primarily by accelerating uptake of MIPLYFFA, while full-year 2025 net revenue surged to $106.5 million from $23.6 million in 2024 and the company swung to net income of $83.2 million from a $105.5 million loss. Strong MIPLYFFA performance, expanding U.S. market access, progress on an EMA review and a global expanded access program, along with advancing its vascular Ehlers-Danlos Phase 3 trial and a year-end cash balance of $238.9 million, position Zevra with greater financial flexibility and strategic optionality as it pursues near-term growth and broader rare-disease market penetration.

The most recent analyst rating on (ZVRA) stock is a Buy with a $24.00 price target. To see the full list of analyst forecasts on Zevra Therapeutics stock, see the ZVRA Stock Forecast page.

Spark’s Take on ZVRA Stock

According to Spark, TipRanks’ AI Analyst, ZVRA is a Neutral.

Zevra Therapeutics’ overall score is driven by strong revenue growth and reasonable valuation, offset by significant challenges in profitability and cash flow management. Technical indicators suggest a bearish trend, but the company’s strategic initiatives and robust financial position provide a foundation for future growth.

To see Spark’s full report on ZVRA stock, click here.

More about Zevra Therapeutics

Zevra Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on therapies for people living with rare diseases, led by its flagship product MIPLYFFA for Niemann-Pick disease type C and supported by additional revenue from OLPRUVA, expanded access programs and AZSTARYS royalties. The company recently relocated its global headquarters to Boston to tap into a deeper, specialized life sciences talent pool and strengthen its position within the rare disease ecosystem.

Average Trading Volume: 876,542

Technical Sentiment Signal: Buy

Current Market Cap: $505.6M

See more data about ZVRA stock on TipRanks’ Stock Analysis page.